Gary Tannenbaum, MD
Vascular Surgery · Bronxville, NYNPI 1811949670
Payments from drug & device makers
What this record shows
This record is dominated by other: $86,015 of the $114,997 with a category attached, or 74.8%. Angiodynamics, Inc. accounts for 94.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2023 at $34,342 and has fallen 78.4% since, to $7,404 in 2025. Among vascular surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $628.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$109K
- Organogenesis Inc.$935
- Endologix LLC$659
- Smith+Nephew$438
- Johnson & Johnson$421
- KCI USA, Inc.$400
- plus $3K from 32 others
What the payments were for
- Consulting fees$4000%
- Food & beverage$5,7785%
- Education$22,80420%
- Other$86,01575%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 15 | $108,837 |
| Organogenesis Inc. | 29 | $935 |
| Endologix LLC | 2 | $659 |
| Smith+Nephew | 16 | $438 |
| Johnson & Johnson | 19 | $421 |
| KCI USA, Inc. | 1 | $400 |
| Terumo Medical Corporation | 14 | $395 |
| Medtronic(2 entities) | 7 | $246 |
| Polynovo North America LLC | 5 | $234 |
| Bard Peripheral Vascular, Inc. | 7 | $234 |
| Stryker | 7 | $232 |
| Philips North America LLC | 7 | $232 |
| Lifenet Health | 1 | $183 |
| Cook Medical LLC | 4 | $160 |
| Medical Device Business Services, Inc. | 1 | $137 |
| Pfizer | 6 | $135 |
| W. L. Gore & Associates, Inc. | 1 | $125 |
| Mozarc Medical US LLC | 1 | $119 |
| AbbVie(2 entities) | 4 | $98 |
| E.r. Squibb & Sons, L.L.C. | 5 | $98 |
| Solventum Corporation | 3 | $86 |
| Regeneron Healthcare Solutions, Inc. | 2 | $76 |
| Resmed Corp | 1 | $59 |
| Tactile Systems Technology Inc | 3 | $46 |
| Integra Lifesciences Corporation | 1 | $45 |
| Cardinal Health 200 LLC | 2 | $39 |
| Abbott | 2 | $38 |
| Hydrofera LLC | 2 | $38 |
| Innovation Technologies Inc | 1 | $37 |
| Urgo Medical North America, LLC | 2 | $35 |
| Penumbra, Inc. | 2 | $33 |
| Baxter Healthcare | 1 | $27 |
| Shockwave Medical, Inc | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $23 |
| Next Science LLC | 2 | $22 |
| Cardiovascular Systems Inc. | 3 | $19 |
| Covidien LP | 1 | $19 |
| Boston Scientific | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$93,375
- Auryon$7,667
- VenaCure 1470 Pro$7,640
- Alto Abdominal Stent Graft System$659
- PREVENA$400
- Apligraf$274
- TheraGenesis Wound Matrix$183
- FlowTriever$167
- STRATAFIX$137
- GORE EXCLUDER AAA Endoprosthesis$125
- PURAPLY WOUND MATRIX$124
- Affinity$124
- NOVACHOR$124
- NuShield$124
- AZUR$122
- MetaCross$122
- Argyle$119
- Endurant$106
- Novosorb BTM$105
How this compares
$114,997 in reported general payments places this provider in the 90th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $23,260 |
| XareltoRivaroxaban | 22 | $19,437 |
| SantylCollagenase Clostridium Hist. | 14 | $7,150 |
| Desonide | 21 | $2,083 |
| Gentamicin Sulfate | 33 | $1,836 |
| ClopidogrelClopidogrel Bisulfate | 73 | $771 |
| Cilostazol | 29 | $525 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $148 |
| Oxycodone Hcl | 13 | $52 |
| Tramadol Hcl | 14 | $38 |
| Atorvastatin Calcium | 12 | $36 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $135 | $23,26039 claims |
| Johnson & JohnsonXarelto | $421 | $19,43722 claims |
| Smith+NephewSantyl | $438 | $7,15014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 405 vascular surgery providers in New York.
Other vascular surgery in Bronxville
- Gary GelbfishNew York$1.9M
- Sundaram RavikumarDobbs Ferry$1.8M
- Antonios GasparisHuntington$1.5M
- Sonya NoorBuffalo$991K
- John LantisNew York$922K
- Brian DerubertisNew York$714K
- James McKinseyNew York$616K
- Peter FariesNew York$494K
- Robert RheeBrooklyn$338K
- Ajit RaoNew York$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.